Vaccine approval does not guarantee equitable access. Critically examine this statement with reference to India's dengue vaccination strategy.

The CDSCO's marketing authorisation for Qdenga (TAK-003), a live-attenuated tetravalent dengue vaccine of Takeda GmbH, is India's first dengue vaccine approval [1]. Yet regulatory clearance is a scientific and legal milestone, not a delivery guarantee — equitable access depends on price, procurement channel and programme integration.

Where approval does advance access

• Regulatory credibility: approval followed a pivotal Phase III study in Indians aged 4–60 years and licensure in 40-plus countries, easing safety hesitancy [1].
• Global assurance: WHO prequalification (2024) opens UN/donor procurement routes and signals manufacturing quality [2].
• No screening barrier: unlike Dengvaxia, Qdenga needs no pre-vaccination serostatus test, removing a costly gatekeeping step for poorer users.
• Domestic pipeline: ICMR–Panacea Biotec's indigenous DengiAll, in a Phase 3 trial across 19 sites with over 10,000 participants, promises future price competition [3].

Why approval alone cannot ensure equity

• Pricing and channel: approval says nothing on cost; a private-market rollout favours urban, insured households, while Aedes vectors are now spreading into semi-urban and rural districts with weaker surveillance.
• No programmatic mandate: inclusion in the National Centre for Vector Borne Diseases Control framework or the Universal Immunisation Programme requires a separate NTAGI-type policy decision, budget line and cold-chain expansion [4].
• Serotype uncertainty: protection is strongest against DENV-2 and DENV-1 but uncertain against DENV-3 and DENV-4 in dengue-naïve persons — rising DENV-3 circulation could blunt real-world benefit.
• Trust deficit: the Dengvaxia episode in the Philippines (2017) shows that weak risk communication and post-marketing surveillance can collapse uptake among the very poor.

Thus the statement holds: approval is necessary but insufficient. Equity demands transparent price negotiation, phased public procurement targeting high-burden districts, robust post-marketing surveillance, and continued vector control — vaccination complementing, not replacing, it. Pairing Qdenga with an affordable indigenous vaccine would align India's dengue strategy with SDG-3 and the constitutional promise of health under Article 21.